HomeAI · summaries
Storia in 18 fonti
Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As Healio previously reported, retatrutide (Eli Lilly), an injectable GIP/GLP-1/glucagon receptor agonist under investigation for the treatment of obesity, type 2 diabetes and other cardio-renal-metabolic disorders, was
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As…
- ·
nbcnews.com
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.
- ·
endpoints.news
Lilly’s triple agonist still leads among late-stage obesity assets
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks. This is the…
- ·
qz.com
Eli Lilly retatrutide Phase 3 obesity trial results 2026
The triple-hormone injection outpaced existing weight loss drugs and approached bariatric surgery outcomes in an 80-week study
- ·
thehindubusinessline.com
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
Eli Lilly's retatrutide shows promise, helping obesity patients lose over 28% of their weight in a key trial.
- ·
eu.usatoday.com
New weight-loss shot more powerful than old GLP-1s, Eli Lilly says
Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.
- ·
zerohedge.com
Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
"We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine."
- ·
valor.globo.com
Eli Lilly diz que novo medicamento ajuda pacientes com obesidade a perder 28% do peso corporal
Resultados do Retatrutida ao longo de um ano e meio, em um estudo, abrem caminho para que a empresa busque aprovação regulatória e lance o medicamento no próximo ano
- ·
independent.co.uk
Super Ozempic? New weight-loss drug sees even better results in recent study
Many of the patients who tested the drug lost about 30 percent of their body weight — a loss comparable to the result of bariatric surgery
- ·
scientificamerican.com
Trial of next-gen weight-loss drug retatrutide shows users lose almost a third of their body weight
While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors
- ·
washingtonexaminer.com
New Eli Lilly weight loss drug has dramatic effects in clinical trial
A new weight loss drug from Eli Lilly made patients lose 28% of their body weight on average, levels achieved only by surgery before.
- ·
time.com
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says
Retatrutide, an experimental injectable drug, targets three hormones related to weight loss.
- ·
economictimes.indiatimes.com
Eli Lilly’s obesity drug shows up to 30% weight loss in trial
Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple…
- ·
benzinga.com
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss - Eli Lilly (NYSE:LLY)
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
- ·
theverge.com
Some people are losing too much weight in Retatrutide trial.
Randomized trial results of the experimental GLP-1, GIP, and glucagon drug shows that it may be too effective, while causing a whopping 11% of participants at the highest dose to…
- ·
upi.com
Eli Lilly: Next-gen weight loss drug may be more effective than others - UPI.com
Eli Lilly's weight loss drug retatrutide helped nearly half of participants in a phase 3 trial to lose more than 30% of their weight after two years.
- ·
expansion.com
La retatrutida de Eli Lilly reduce la obesidad en un 30% a los dos a�os de tratamiento
Los resultados preliminares del estudio TRIUMPH-1 confirman resultados anteriores en fase II de la retatrutida (LY3437943), f�rmaco en fase experimental de la familia de los…
- ·
g1.globo.com
Nova caneta contra obesidade leva pacientes a perder até 32 kg em estudo de fase 3 | G1
Retatrutida, molécula da Eli Lilly ainda em investigação, mostrou perda média de 28,3% do peso corporal em 80 semanas; resultado se aproxima de índices observados em cirurgias…